[go: up one dir, main page]

WO2009030224A3 - Nouveaux produits pharmaceutiques, procédés pour les produire et leur utilisation en thérapie médicale - Google Patents

Nouveaux produits pharmaceutiques, procédés pour les produire et leur utilisation en thérapie médicale Download PDF

Info

Publication number
WO2009030224A3
WO2009030224A3 PCT/DE2008/001528 DE2008001528W WO2009030224A3 WO 2009030224 A3 WO2009030224 A3 WO 2009030224A3 DE 2008001528 W DE2008001528 W DE 2008001528W WO 2009030224 A3 WO2009030224 A3 WO 2009030224A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancerous diseases
quinazoline compounds
treating cancerous
novel quinazoline
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2008/001528
Other languages
German (de)
English (en)
Other versions
WO2009030224A2 (fr
Inventor
Hans Scheefers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ScheBo Biotech AG
Original Assignee
ScheBo Biotech AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE200810012435 external-priority patent/DE102008012435A1/de
Application filed by ScheBo Biotech AG filed Critical ScheBo Biotech AG
Publication of WO2009030224A2 publication Critical patent/WO2009030224A2/fr
Publication of WO2009030224A3 publication Critical patent/WO2009030224A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux produits pharmaceutiques, des procédés pour les produire et leur utilisation en thérapie médicale, notamment pour traiter le cancer.
PCT/DE2008/001528 2007-09-07 2008-09-08 Nouveaux produits pharmaceutiques, procédés pour les produire et leur utilisation en thérapie médicale Ceased WO2009030224A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE102007044564 2007-09-07
DE102007044564.6 2007-09-07
DE102008012435.4 2008-02-29
DE200810012435 DE102008012435A1 (de) 2008-02-29 2008-02-29 Neue Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Therapie
DE102008045244 2008-08-29
DE102008045244.0 2008-08-29

Publications (2)

Publication Number Publication Date
WO2009030224A2 WO2009030224A2 (fr) 2009-03-12
WO2009030224A3 true WO2009030224A3 (fr) 2009-08-13

Family

ID=40361674

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2008/001528 Ceased WO2009030224A2 (fr) 2007-09-07 2008-09-08 Nouveaux produits pharmaceutiques, procédés pour les produire et leur utilisation en thérapie médicale

Country Status (1)

Country Link
WO (1) WO2009030224A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009019852A1 (de) 2009-05-06 2010-11-11 Schebo Biotech Ag Polymere mit neuen Strukturelementen, Verfahren zu ihrer Herstellung und ihre Verwendung
CN103228141B (zh) 2010-09-03 2016-04-20 拜耳知识产权有限责任公司 取代的稠合的嘧啶酮和二氢嘧啶酮
AU2014216178B2 (en) 2013-02-15 2018-06-28 KALA BIO, Inc. Therapeutic compounds and uses thereof
KR102277833B1 (ko) 2013-02-20 2021-07-14 칼라 파마슈티컬스, 인크. 치료 화합물 및 그의 용도
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CA2928658A1 (fr) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Formes cristallines de composes therapeutiques et leurs utilisations
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (fr) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Formes cristallines de composes therapeutiques et leurs utilisations
WO2019071351A1 (fr) * 2017-10-12 2019-04-18 Trillium Therapeutics Inc. Nouveaux dérivés de 4-aryloxyquinazoline fluorés utilisés en tant qu'inhibiteurs d'egfr utiles pour le traitement de cancers
CN107840843A (zh) * 2017-10-17 2018-03-27 浙江工业大学义乌科学技术研究院有限公司 一种西地尼布中间体的合成方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038983A1 (fr) * 1996-04-12 1997-10-23 Warner-Lambert Company Inhibiteurs irreversibles de tyrosine kinases
WO2001012604A1 (fr) * 1999-08-18 2001-02-22 Aventis Cropscience Gmbh Fongicides
WO2001021594A1 (fr) * 1999-09-21 2001-03-29 Astrazeneca Ab Composes de quinazoline et compositions pharmaceutiques comprenant lesdits composes
EP1110953A1 (fr) * 1995-03-30 2001-06-27 Pfizer Inc. Dérivés de quinazolinone
EP1510221A1 (fr) * 2002-06-03 2005-03-02 Mitsubishi Pharma Corporation Moyens preventifs et/ou therapeutiques destines a des sujets presentant l'expression ou l'activation de her2 et/ou egfr
EP1553097A1 (fr) * 1999-02-10 2005-07-13 AstraZeneca AB Derives de quinazoline utilises comme inhibiteurs de l'angiogenese et produits intermediares

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1110953A1 (fr) * 1995-03-30 2001-06-27 Pfizer Inc. Dérivés de quinazolinone
WO1997038983A1 (fr) * 1996-04-12 1997-10-23 Warner-Lambert Company Inhibiteurs irreversibles de tyrosine kinases
EP1553097A1 (fr) * 1999-02-10 2005-07-13 AstraZeneca AB Derives de quinazoline utilises comme inhibiteurs de l'angiogenese et produits intermediares
WO2001012604A1 (fr) * 1999-08-18 2001-02-22 Aventis Cropscience Gmbh Fongicides
WO2001021594A1 (fr) * 1999-09-21 2001-03-29 Astrazeneca Ab Composes de quinazoline et compositions pharmaceutiques comprenant lesdits composes
EP1510221A1 (fr) * 2002-06-03 2005-03-02 Mitsubishi Pharma Corporation Moyens preventifs et/ou therapeutiques destines a des sujets presentant l'expression ou l'activation de her2 et/ou egfr

Also Published As

Publication number Publication date
WO2009030224A2 (fr) 2009-03-12

Similar Documents

Publication Publication Date Title
WO2009030224A3 (fr) Nouveaux produits pharmaceutiques, procédés pour les produire et leur utilisation en thérapie médicale
WO2009050506A3 (fr) Combinaison 059
WO2009011850A3 (fr) Nouveaux composés thérapeutiques
UA98125C2 (ru) Замещенные дигидропиразолоны для лечения сердечно-сосудистых и гематологических заболеваний
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
WO2008085794A3 (fr) Méthodes et compositions associées à des composés adhérant aux caillots
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
WO2006058868A3 (fr) Pteridines substituees destinees au traitement de maladies inflammatoires
WO2007115620A3 (fr) Nouveaux composés de cyclobutyle en tant qu'inhibiteurs de kinase
WO2009074827A3 (fr) Combinaison comprenant un inhibiteur de mek et un inhibiteur de la kinase aurora 188
WO2006102504A3 (fr) Combinaisons destinees au traitement de cancer
WO2008138904A3 (fr) Composés antagonistes de l'arn modulamt le her3
MY186456A (en) Quinazoline carboxamide azetidines
WO2008076954A3 (fr) Composés hétérocycliques et procédés d'utilisation de ceux-ci
WO2007109279A3 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
WO2010075280A3 (fr) Composés à base de coumarine
WO2009074247A8 (fr) Nouveaux dérivés d'amide d'acide 2-arylthiazole-4-carboxylique, leur préparation et leur utilisation en tant que médicament
WO2008060945A3 (fr) Diagnostic et traitement du cancer du sein
WO2010121675A3 (fr) Thiazolyl-benzimidazoles
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
WO2009136997A3 (fr) Inhibiteurs des cathepsines l, b et s humaines
WO2010072770A3 (fr) Analogues de griséofulvine pour le traitement du cancer par inhibition de l'agrégat centrosomial
WO2004087700A8 (fr) Derives du benzenesulfonamide, leur procede de preparation et leur utilisation de la douleur
WO2006034491A3 (fr) Composes a base de quinoleine et de quinazoline a substitution phenylique pour le traitement du diabete

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 08801321

Country of ref document: EP

Kind code of ref document: A2